Tags

Type your tag names separated by a space and hit enter

Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients.
J Pediatr Endocrinol Metab 2011; 24(7-8):489-96JP

Abstract

BACKGROUND

Growth hormone deficiency (GHD) in children is treated with daily subcutaneous injections of GH. Poor adherence, resulting in suboptimal treatment outcomes, is common due to long-term treatment. Injection devices that are considered easy to use by patients or guardians could improve adherence.

OBJECTIVE

This study assessed the usability of the Norditropin FlexPro pen injector and NovoTwist needles (both Novo Nordisk A/S, Bagsvaerd, Denmark) in Japanese children and adolescents with GHD.

METHODS

This open-label, uncontrolled usability test included patients aged 6 to < or = 18 years with GHD currently receiving daily injections of GH with pen injectors. Patients performed repeated injections of test medium into a foam cushion. Patients or guardians completed a questionnaire on pen handling.

RESULTS

A total of 73/74 patients (99%) rated Norditropin FlexPro easy to handle, reporting no technical complaints. In total, 60 (81%) preferred Norditropin FlexPro over their current device, with 12% preferring their current device and 7% not sure.

CONCLUSIONS

Norditropin FlexPro was perceived as easy to use and reliable, and was well accepted and preferred over the current device for the administration of GH in children and adolescents. Patients were more confident that Norditropin FlexPro delivered the right dose compared with their current device.

Authors+Show Affiliations

University of Aarhus and Growth Hormone Global Marketing, Novo Nordisk A/S, Virum, Denmark. amk@novonordisk.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21932587

Citation

Kappelgaard, Anne-Marie, et al. "Patient Preference for a New Growth Hormone Injection Device: Results of an Open-label Study in Japanese Pediatric Patients." Journal of Pediatric Endocrinology & Metabolism : JPEM, vol. 24, no. 7-8, 2011, pp. 489-96.
Kappelgaard AM, Mikkelsen S, Knudsen TK, et al. Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients. J Pediatr Endocrinol Metab. 2011;24(7-8):489-96.
Kappelgaard, A. M., Mikkelsen, S., Knudsen, T. K., & Fuchs, G. S. (2011). Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients. Journal of Pediatric Endocrinology & Metabolism : JPEM, 24(7-8), pp. 489-96.
Kappelgaard AM, et al. Patient Preference for a New Growth Hormone Injection Device: Results of an Open-label Study in Japanese Pediatric Patients. J Pediatr Endocrinol Metab. 2011;24(7-8):489-96. PubMed PMID: 21932587.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients. AU - Kappelgaard,Anne-Marie, AU - Mikkelsen,Søren, AU - Knudsen,Thomas Kamp, AU - Fuchs,Gitte Schøning, PY - 2011/9/22/entrez PY - 2011/9/22/pubmed PY - 2011/10/25/medline SP - 489 EP - 96 JF - Journal of pediatric endocrinology & metabolism : JPEM JO - J. Pediatr. Endocrinol. Metab. VL - 24 IS - 7-8 N2 - BACKGROUND: Growth hormone deficiency (GHD) in children is treated with daily subcutaneous injections of GH. Poor adherence, resulting in suboptimal treatment outcomes, is common due to long-term treatment. Injection devices that are considered easy to use by patients or guardians could improve adherence. OBJECTIVE: This study assessed the usability of the Norditropin FlexPro pen injector and NovoTwist needles (both Novo Nordisk A/S, Bagsvaerd, Denmark) in Japanese children and adolescents with GHD. METHODS: This open-label, uncontrolled usability test included patients aged 6 to < or = 18 years with GHD currently receiving daily injections of GH with pen injectors. Patients performed repeated injections of test medium into a foam cushion. Patients or guardians completed a questionnaire on pen handling. RESULTS: A total of 73/74 patients (99%) rated Norditropin FlexPro easy to handle, reporting no technical complaints. In total, 60 (81%) preferred Norditropin FlexPro over their current device, with 12% preferring their current device and 7% not sure. CONCLUSIONS: Norditropin FlexPro was perceived as easy to use and reliable, and was well accepted and preferred over the current device for the administration of GH in children and adolescents. Patients were more confident that Norditropin FlexPro delivered the right dose compared with their current device. SN - 0334-018X UR - https://www.unboundmedicine.com/medline/citation/21932587/Patient_preference_for_a_new_growth_hormone_injection_device:_results_of_an_open_label_study_in_Japanese_pediatric_patients_ L2 - https://www.degruyter.com/doi/10.1515/jpem.2011.252 DB - PRIME DP - Unbound Medicine ER -